Literature DB >> 19458705

Cancer: Melanoma troops massed.

Paul H Huang, Richard Marais.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19458705     DOI： 10.1038/459336a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  The emerging power of chemical genetics.

Authors:  Kimberly M Specht; Kevan M Shokat
Journal:  Curr Opin Cell Biol       Date:  2002-04       Impact factor: 8.382

3.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

Authors:  Mathew J Garnett; Sareena Rana; Hugh Paterson; David Barford; Richard Marais
Journal:  Mol Cell       Date:  2005-12-22       Impact factor: 17.970

4.  CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation.

Authors:  Daniel A Ritt; Ming Zhou; Thomas P Conrads; Timothy D Veenstra; Terry D Copeland; Deborah K Morrison
Journal:  Curr Biol       Date:  2006-12-14       Impact factor: 10.834

5.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors:  Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 6.  Protein kinase CK2 as a druggable target.

Authors:  Stefania Sarno; Lorenzo A Pinna
Journal:  Mol Biosyst       Date:  2008-06-12

7.  Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.

Authors:  William M Old; John B Shabb; Stephane Houel; Hong Wang; Kasey L Couts; Chia-Yu Yen; Elizabeth S Litman; Carrie H Croy; Karen Meyer-Arendt; Jose G Miranda; Robert A Brown; Eric S Witze; Rebecca E Schweppe; Katheryn A Resing; Natalie G Ahn
Journal:  Mol Cell       Date:  2009-04-10       Impact factor: 17.970

Review 8.  Melanoma biology and new targeted therapy.

Authors:  Vanessa Gray-Schopfer; Claudia Wellbrock; Richard Marais
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962
  8 in total
  6 in total

Review 1.  B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.

Authors:  Cynthia Shepherd; Igor Puzanov; Jeffrey A Sosman
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

Review 2.  Targeted therapy in rare cancers--adopting the orphans.

Authors:  Javier Munoz; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

Review 3.  Targeting tumor cell motility as a strategy against invasion and metastasis.

Authors:  Alan Wells; Jelena Grahovac; Sarah Wheeler; Bo Ma; Douglas Lauffenburger
Journal:  Trends Pharmacol Sci       Date:  2013-04-06       Impact factor: 14.819

4.  Evidence of melanoma in wild marine fish populations.

Authors:  Michael Sweet; Nigel Kirkham; Mark Bendall; Leanne Currey; John Bythell; Michelle Heupel
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

5.  In vitro and in vivo cytotoxic activity of human lactoferricin derived antitumor peptide R-DIM-P-LF11-334 on human malignant melanoma.

Authors:  Sabrina Riedl; Beate Rinner; Helmut Schaider; Bernadette Liegl-Atzwanger; Katharina Meditz; Julia Preishuber-Pflügl; Sarah Grissenberger; Karl Lohner; Dagmar Zweytick
Journal:  Oncotarget       Date:  2017-05-11

6.  Multiparametric analysis of cell-free DNA in melanoma patients.

Authors:  Francesca Salvianti; Pamela Pinzani; Paolo Verderio; Chiara Maura Ciniselli; Daniela Massi; Vincenzo De Giorgi; Marta Grazzini; Mario Pazzagli; Claudio Orlando
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.